Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa
Executive Summary
Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.
You may also be interested in...
J.P. Morgan Notebook, Jan. 15: Kite, Vivus, Amarin
“The Pink Sheet” DAILY’s round-up of news and notes from the last day of the J.P. Morgan Healthcare Conference in San Francisco.
Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch
With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.
Amarin Raises $100M Debt Funding As It Preps For Vascepa Launch
With no partner or buyer ready to complete a transaction, Amarin prepares to market an approved fish-oil pill on its own. A new hybrid debt vehicle will tide it over until it receives more clarity around an NCE designation and a second indication, which it hopes could eventually lead to a deal.